INGREZZA real-world patient cases in tardive dyskinesia

See results with INGREZZA from real-world patients

Review tardive dyskinesia (TD) movements across a broad range of adult patients and see the effect of treatment with INGREZZA^® (valbenazine) capsules.

Real-world patient cases

Real-world cases feature patients treated with INGREZZA in clinical practice, and not from the INGREZZA clinical trial program. Treatment decisions were based on healthcare providers’ clinical judgment.

These patients were compensated by Neurocrine Biosciences, Inc., and have consented to Neurocrine’s use of the videos and their protected health information.

Debra, a real-world TD patient treated with INGREZZA

Debra

Major depressive disorder

Debra baseline, video

Debra at 6 weeks, video

INGREZZA treatment:

INGREZZA 40 mg (Weeks 0–5) then INGREZZA 80 mg (Weeks 5–6)^a

Medical history:

Woman in her 50s living with severe major depressive disorder
Previously treated with anticholinergic

Relevant treatment:

Second-generation antipsychotics, which resulted in TD

Relevant concomitant treatment at baseline:

Aripiprazole, quetiapine, escitalopram, buspirone, amantadine

TD history:

Developed choreoathetoid movements 6 months prior to treatment with INGREZZA
Presented with predominant trunk movements and abnormal movements of mouth and lips

Note: Not all movements may be visible in these videos

INGREZZA treatment results:

At 6 weeks, HCP noted torso and overall body movements were improved in intensity
HCP notes patient did have some mouth and lip movements

Gloria, a real-world TD patient treated with INGREZZA

Gloria

Schizoaffective disorder and depression

Gloria baseline, video

Gloria at 2 weeks, video

Gloria at 6 weeks, video

INGREZZA treatment:

INGREZZA 40 mg (Week 1) then INGREZZA 80 mg (Weeks 2–6)^a

Medical history:

Woman in her 50s living with schizoaffective disorder and depression
History of hospitalization, but circumstances were unknown

Relevant treatment:

Second-generation antipsychotics, which resulted in TD
Currently taking anticholinergic, but medical records were unavailable

Relevant concomitant treatment at baseline:

Paliperidone palmitate 156 mg/QM, fluoxetine 40 mg/QD, benztropine 2 mg/BID

TD history:

Presented with predominant jaw/mouth, hand, and foot movements
Patient’s severe hand movement impacted self-feeding; she was also unable to communicate well due to tongue movements

Note: Not all movements may be visible in these videos

INGREZZA treatment results:

At 2 weeks, symptoms showed improvement and HCP noted patient was more communicative
Patient experienced somnolence
At 4-week follow-up visit, HCP instructed patient to take INGREZZA HS
At 6 weeks, patient’s family noted that movements were improved; HCP noted severe hand movements were reduced, enabling patient to self-feed

Dan, a real-world TD patient treated with INGREZZA

Dan

Schizoaffective disorder (bipolar type) and unspecified anxiety disorder

Dan baseline, video

Dan at 8 weeks, video

Dan at 16 weeks, video

INGREZZA treatment:

INGREZZA 40 mg (Weeks 0–8) then INGREZZA 80 mg (Weeks 9–16)^a

Medical history:

Man in his 20s living with schizoaffective disorder (bipolar type) & unspecified anxiety disorder

Relevant treatment:

First-generation and second-generation antipsychotics, which resulted in TD
Previously treated with anticholinergic for drug-induced movement disorder (DIMD)

Relevant concomitant treatment at baseline:

Paliperidone palmitate 819 mg/Q3M, perphenazine 4 mg/BID, trihexyphenidyl HCl 2 mg/BID

TD history:

Diagnosed with TD approximately 1 year prior to treatment with INGREZZA
Presented with predominantly jaw, tongue, and hand movements
Patient complained of jaw pain; his dentist found the pain unrelated to a joint or muscular issue

Note: Not all movements may be visible in these videos

INGREZZA treatment results:

At 8 weeks, HCP noted movements were greatly improved from baseline
At 16 weeks, HCP noted movements were “mild” and “minimal” for lips, perioral area, and jaw
Patient noted that he no longer had jaw movement or pain due to jaw dyskinesia

Martin, a real-world TD patient treated with INGREZZA

Martin

Schizophrenia

Martin baseline, video

Martin at 6 weeks, video

INGREZZA treatment:

INGREZZA 40 mg (1 month) then INGREZZA 80 mg (after 1 month)^a

Medical history:

Man in his 70s living with schizophrenia for over 30 years

Relevant treatment:

First-generation antipsychotic, which resulted in TD
Previously treated with anticholinergic for drug-induced movement disorder (DIMD), to no effect

Relevant concomitant treatment at baseline:

Lorazepam 1 mg/TID, haloperidol 3 mg

TD history:

Presented with primarily mouth movements as well as some hand movements

Note: Not all movements may be visible in these videos

INGREZZA treatment results:

At 6 weeks, HCP noted symptoms were better controlled with less pronounced mouth movements

Felix, a real-world TD patient treated with INGREZZA

Felix

Schizoaffective disorder

Felix baseline, video

Felix at 6 weeks, video

INGREZZA treatment:

INGREZZA 40 mg (Weeks 0–2) then INGREZZA 80 mg (Weeks 2–6)^a

Medical history:

Man in his 70s living independently with schizoaffective disorder for 30 years

Relevant treatment:

First-generation antipsychotic, which resulted in TD
Prior exposure to several first-generation antipsychotics

Relevant concomitant treatment at baseline:

Haloperidol 5 mg/QD, amitriptyline 50 mg/HS, trifluoperazine 15 mg/QD

TD history:

Developed abnormal movements of the mouth several years prior to treatment with INGREZZA
Presented with primarily orobuccal movements as well as movements of the hands and feet

Note: Not all movements may be visible in these videos

INGREZZA treatment results:

At 6 weeks, HCP noted symptoms look better controlled with less pronounced lip and jaw movements
HCP notes patient did have some tongue and hand movements

Maureen, a real-world TD patient treated with INGREZZA

Maureen

Bipolar disorder

Maureen baseline, video

Maureen at 31 months, video

INGREZZA treatment:

INGREZZA 40 mg (Week 1) then INGREZZA 80 mg (Week 2–Month 31)^a

Medical history:

Woman in her 50s living with bipolar disorder

Relevant treatment:

Second-generation antipsychotic, which resulted in TD

Relevant concomitant treatment at baseline:

Quetiapine 400 mg/QD

TD history:

Developed abnormal movements of the lips and jaw approximately 5 to 6 years before treatment with INGREZZA
Presented with primarily orobuccal movements and jaw pain

Note: Not all movements may be visible in these videos

INGREZZA treatment results:

At 31 months, HCP noted absence of orobuccal movements and jaw pain

^a

Patients were not a part of the INGREZZA clinical trials. Patients’ treating healthcare providers assessed for TD. Recordings were taken before initiation of INGREZZA and at follow-up after 6 weeks of treatment for Debra, Martin, and Felix, after 2 and 6 weeks of treatment for Gloria, after 8 and 16 weeks of treatment for Dan, and after 31 months for Maureen. Treatment decisions were based on healthcare providers’ clinical judgment. These patients were compensated by Neurocrine Biosciences, Inc., and have consented to Neurocrine's use of the videos and their protected health information.

SIMPLE FROM THE START

Only INGREZZA offers a therapeutic dose from Day 1¹

PATIENT-REPORTED OUTCOMES WITH INGREZZA

The first and only VMAT2 inhibitor to demonstrate clinically meaningful reductions in patient-reported TD impact²

REVIEW PRO DATA

CONNECT WITH A REPRESENTATIVE

Request an office visit from a Neurocrine representative for additional information, patient resources, or samples of INGREZZA

REQUEST INFO

REFERENCES:

INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.
Data on file. Neurocrine Biosciences, Inc.

Important Safety Information

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and

Important Information

INDICATION & USAGE

INGREZZA^® (valbenazine) capsules and INGREZZA^® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.